e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis
Oxlade O., Falzon D., Menzies D.
Source:
Eur Respir J 2012; 39: 626-634
Journal Issue:
March
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Oxlade O., Falzon D., Menzies D.. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. Eur Respir J 2012; 39: 626-634
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Strategies against multidrug-resistant tuberculosis
Source: Eur Respir J 2002; 20: 66S-77S
Year: 2002
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Clinical and operational value of the extensively drug-resistant tuberculosis definition
Source: Eur Respir J 2007; 30: 623-626
Year: 2007
Molecular surveillance of multi-drug resistant tuberculosis in Europe
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay
Source: Eur Respir J 2013; 41: 1163-1171
Year: 2013
Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection
Source: Eur Respir J 2010; 36: 1242-1247
Year: 2010
The problem of multi-drug resistant (MDR)-TB
Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties
Year: 2005
The WHO strategy for TB control and elimination
Source: Eur Respir Mon 2012; 58: 242-253
Year: 2012
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Microbiology of
Mycobacterium tuberculosis
and a new diagnostic test for TB
Source: Eur Respir Mon 2012; 58: 1-13
Year: 2012
Recent transmission of drug resistant
M. tuberculosis
in Latvia
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012
Patient choice promotes adherence in preventive treatment for latent tuberculosis
Source: Eur Respir J 2007; 30: 728-735
Year: 2007
Cost-effectiveness of two latent tuberculosis infection screening strategies
Source: International Congress 2018 – Current practices in and attitudes to screening for tuberculosis, and a discussion about genetic diversity
Year: 2018
Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
TB drug resistance in high-incidence countries
Source: Eur Respir Mon 2012; 58: 95-110
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept